Economic Burden of Adverse Events Associated With Follow-Up Frequency Among Patients With Metastatic Melanoma
Phase of Trial: Phase IV
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 04 Oct 2017 Status changed from active, no longer recruiting to completed.
- 14 Sep 2017 Planned End Date changed from 28 Dec 2017 to 30 Sep 2017.
- 14 Sep 2017 Planned primary completion date changed from 28 Dec 2017 to 30 Sep 2017.